Showing results (41-50 of 70) with videos related to
Sort By:
Pageof 7
Journal of Clinical Psychopharmacology|February 11, 2016
Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 StudyAzmi F Nasser, David C Henderson, Maurizio Fava, et al.Regulatory Toxicology and Pharmacology : RTP|December 19, 2009
Further considerations on the evaluation of potential reduced-risk tobacco products. Part II: Re-assessment of a heuristic using the CPS-II databaseLenn Murrelle, Christopher R E Coggins, Chris Gennings, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 28, 2014
Liquid chromatography/tandem mass spectrometry method for simultaneous determination of cocaine and its metabolite (-)ecgonine methyl ester in human acidified stabilized plasma samplesYongzhen Liu, Bo Zheng, Stephanie Strafford, et al.Contemporary Clinical Trials|December 4, 2018
Remission from chronic opioid use-Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristicsWalter Ling, Vijay R Nadipelli, Naoko A Ronquest, et al.Journal of Substance Abuse Treatment|January 19, 2020
Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term studyWalter Ling, Vijay R Nadipelli, Caitlyn T Solem, et al.Journal of Clinical Psychopharmacology|December 10, 2015
Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use DisorderAzmi F Nasser, Mark K Greenwald, Bradley Vince, et al.Bioorganic & Medicinal Chemistry Letters|August 10, 2010
[3-azabicyclo[3.1.0]hex-1-yl]phenyl-benzenesulfonamides as selective dopamine D3 antagonistsFabrizio Micheli, Dieter Hamprecht, Giorgio Bonanomi, et al.Psychopharmacology|November 7, 2007
The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in ratsKrista Spiller, Zheng-Xiong Xi, Xiao-Qing Peng, et al.Patient Preference and Adherence|July 17, 2019
Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical studyRahul Dhanda, Della Varghese, Vijay R Nadipelli, et al.Substance Abuse and Rehabilitation|June 27, 2019
Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness AssessmentWalter Ling, Vijay R Nadipelli, Caitlyn T Solem, et al.Pageof 7